Ryanodine receptors are targeted by anti-apoptotic $Bcl-X_L$ involving its BH4 domain and Lys87 from its BH3 domain

Tim Vervliet¹, Irma Lemmens², Elien Vandermarliere³, Elke Decrock⁴, Hristina Ivanova¹, Giovanni Monaco¹, Vincenzo Sorrentino⁵, Nael Nadif Kasri⁶, Ludwig Missiaen¹, Lennart Martens³, Humbert De Smedt¹, Luc Leybaert⁴, Jan B. Parys¹, Jan Tavernier², Geert Bultynck^{1*}

Affiliations

1 KU Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine,B-3000 Leuven, Belgium

2 University of Gent, Cytokine Receptor Lab, VIB Department of Medical Protein Research, B-9000 Gent, Belgium

3 University of Gent, Computational Omics and Systems Biology Group, VIB Department of Medical Protein Research, B-9000 Gent, Belgium

4 University of Gent, Physiology Group, Department of Basic Medical Sciences, B-9000 Gent, Belgium

5 University of Siena, Molecular Medicine Section, Department of Molecular and Developmental Medicine, and Interuniversitary Institute of Myology, 53100 Siena, Italy

6 Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Department of Human Genetics, 6500HB Nijmegen, The Netherlands

* Corresponding author:

Name:	Geert Bultynck		
Address:	Laboratory of Molecular and Cellular Signaling,		
	Department of Cellular and Molecular Medicine, KU Leuven		
	Campus Gasthuisberg, O&N I Herestraat 49 - bus 802, B-3000 Leuven Belgium		
e-mail:	geert.bultynck@med.kuleuven.be	Telephone:	+32 16 330215





Supplementary Figure 2: SPR sensorgram showing binding of a BH4-Bcl-X_L recognizing antibody to the immobilized biotin-BH4-Bcl-X_L. The trace was corrected for background binding by subtracting binding to the scrambled biotin-BH4-Bcl-X_L. The black arrow indicates the start of the association phase; the grey arrow indicates the start of the dissociation phase.